27 / 30
PHASE III TRIALS COMPARISON: SAFETY
Cabozantinib Regorafenib Ramucirumab*
Dose Reduction, % patients
62
68
5**
AE related Discontinuation Rate, %
16
25
18
Median Duration Treatment, months
3.8
3.6
3.0
Grade 3-4 Aes, % patients
68
56
35
* REACH 2 Trial
**Only Dose reduction, no delayed or omitted doses